Industry Relations Council

AANN Industry Relations Council (IRC) membership is available to organizations that support the goals and mission of AANN.

The goal of the IRC is to provide a format to build positive relationships and foster dialogue among key industry representatives who have ties to the specialty of neuroscience, to gain a greater understanding of mutual areas of interest, and to further programs that benefit patients and their families, neuroscience nurses, and other allied healthcare professionals

Partnership in the IRC is for 1 year. It is a nonvoting partnership with benefits extended to a single corporate-designated representative. The IRC program features tiered participation levels to allow companies of all sizes to enhance their engagement with AANN. Partnership is available at a corporate ($3,500) or executive ($13,000) level.

Benefits of IRC participation include

  • 30 minute to a 1-hour meeting between company representatives and a select group of AANN Board members and staff to discuss topics of mutual interest
  • a chance to survey the AANN Membership
  • an opportunity to send an e-blast to AANN members (sent by AANN on your behalf)
  • registration for IRC representatives at the AANN annual meeting
  • invitation to the President's Reception with AANN board members
  • recognition throughout the year on the AANN website, on signage at the Annual Educational Meeting, and in the program guide, which is distributed to all meeting attendees.

Download the IRC Application

Industry Relations Council Members

AANN proudly recognizes the following IRC corporate partners and thanks to them for their support. Please note, AANN does not endorse any company or product.

Executive Level

AZ logo


AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZenecaUS. In an effort to streamline access to comprehensive medical information about AstraZeneca products and resources, we have developed an online medical and scientific information portal for healthcare professionals practicing in the United States. This online portal can be accessed at

Eisai1 edit


As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at and follow us on Twitter and LinkedIn.

Learn about patient assistance on Eisai's website
View clinical trial information
View another clinical trial

Ella the Jellyfish The first Amazon Alexa skill designed for those affected by Lennox-Gastaut Syndrome (LGS). Ella the Jellyfish was created with input from children living with LGS, a rare and severe form of childhood-onset epilepsy, their families and caregivers and is provided free of charge. Featuring capabilities such as interactive play, listening, and creative activities, Ella the Jellyfish was designed for easy and seamless daily use on Alexa-enabled devices, including voice assistants, mobile phones and tablets. By simply saying, “Alexa, open Ella the Jellyfish,” families, caregivers and children can instantly and easily interact with Ella and her underwater friends by listening to Ella tell a story, singing a song, listening to a relaxing meditation or playing such games as “Ella Says, Freeze Dance” and “Color Hunt.” 

View a Facebook Live event focused on epilepsy during the upcoming American Epilepsy Society (AES) annual meeting. 
Hosted on the Jumo Health Facebook Page:

Neurelis Logo Combination

Neurelis, Inc.

Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system (CNS) market. Neurelis is leveraging its expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates, such as NRL-1 for the treatment of acute repetitive or cluster seizures, to address significant unmet medical needs. NRL-1 (intranasal diazepam) is a proprietary formulation of diazepam, delivered via a nasal formulation in a spray, being developed for the management of pediatric and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures. NRL-1 has been granted Orphan Drug and Fast Track Designations by the FDA. In clinical trials, NRL-1 has demonstrated high bioavailability, low variability from dose to dose, and was well-tolerated - with reliable dosing, regardless of when administered.

January 2020 Update:

Neurelis announces the FDA approval of VALTOCO, the first nasal seizure rescue medication for ages 6 and above – read the Press Release for details.
Patient service program, myNEURELIS™ (1-866-696-3873). For more information on VALTOCO, please visit



Neurocrine Bioscences

Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders. The company discovered, developed, and marketed INGREZZA® (valbenazine) capsules, the first FDA-approved product for the treatment of adults with tardive dyskinesia, an involuntary movement disorder. Neurocrine's clinical development programs includes opicapone as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in Parkinson's disease patients.

Clinical trials:

Persistance of Effect and Safety of Valbenzaine for the Treatment of Tardive Dyskinesia

VY-AADDC02 for Parkinson's Disease With Motor Fluctutations


Corporate Level



Arbor Pharmaceuticals is an Atlanta, GA based specialty pharmaceutical company which currently markets prescription products for the cardiovascular, hospital and pediatric markets.


View More Support Opportunities